Tobacco Asia

Tobacco Asia 23 "FDA has given Zyn the ability to tell their customers, and consumers at large, that their products have markedly lower risk than cigarettes," said Laura Leigh Oyler, regulatory affairs vice president for Haypp Group and its subsidiary Nicokick.com. "While this is not the first MRTP ever granted, it is the first one given to a product with mass consumer appeal. "At a time when misconceptions about the risk of nicotine are high, the ability to communicate this is monumental not just for the alternative nicotine industry, but for policy makers, public health leaders, and responsible retailers who can shift the conver- sation from fear-based, while keeping youth prevention front and center. "Americans can finally hear the truth about lower-risk nicotine pouches." The agency also retains authority to withdraw the orders if continued marketing no longer benefits public health, including if youth uptake increases significantly. "Being able to use a modified risk claim is a meaningful milestone for tobacco harm reduction," said Shem Baldeosingh, director of the Global Institute for Novel Nicotine (GINN). "It signals growing recognition that non-combustible nicotine pouches, when appropri- ately regulated, can help reduce the burden of smoking-related disease. "Significantly, the FDA's post-market surveillance requirements will strengthen the evidence base even further — generating real world insights into usage patterns, behavior, and public health impact. This is a clear example of science-based, propor- tionate regulation in practice." FDA has authorized 26 nicotine pouch products for sale in the United States. The Zyn MRTP orders also establish the first FDA-authorized reduced risk messaging for nicotine pouches, potentially providing a regulatory framework for future MRTP applications by other manufacturers. "This decision proves that a light-touch, evidence-based approach delivers for consumers," said David Williams, president of the Taxpayers Protection Alliance. "The FDA's authorization of Zyn products with an MRTP claim shows that policymakers can embrace harm reduction without resorting to bans or heavy-handed mandates. "Consumers deserve accurate information about less harmful alternatives to cigarettes. And adults deserve the freedom to choose less harmful alternatives without Washington bureaucrats second-guessing their decisions." Martin Miller, e.v.p. of business development at IKE Tech, said the decision also underscores that product and regulatory innovation must advance together. "FDA continues to place significant emphasis on youth access prevention and ongoing post-market oversight, reinforcing that compliance doesn't end at authoriza- tion or at the point of sale," said Miller. "As more products enter the market, the in- dustry will need infrastructure that connects verified users, authenticated products and enforceable compliance throughout the product lifecycle." A clearer regulatory direction One thing has become increasingly clear through the first half of 2026. Rather than relying primarily on enforcement after products enter the marketplace, FDA is work- ing to establish a more structured regulatory framework—one that encourages manu- facturers to follow the legal pathway, demands greater accountability from companies supplying the US market, and rewards those that can demonstrate their products meet the agency's public health standard. Whether that approach ultimately reduces the number of unauthorized products on the market remains to be seen. The foreign manufacturer registration rules would be burdensome for small manufacturers, and FDA has authorized only one vaping product brand from a company not affiliated with a major tobacco company. The en- forcement guidelines may encourage companies that want to remain in the US market to submit more complete, better-supported PMTA rather than relying on a "market first, deal with FDA later" strategy. However, PMTAs remain costly and burdensome, especially for small manufacturers. At the very least, FDA's recent actions provide the industry with greater regulato- ry clarity. For companies worldwide—particularly in Asia—that manufacture nicotine products destined for the United States, understanding the agency's evolving regulatory framework may soon be as important as understanding the products themselves.

• Cover